Immunogenicity comparison of interferon beta-1a preparations using the BALB/c mouse model: assessment of a new formulation for use in multiple sclerosis.

The in vivo immunogenicity of a new interferon (IFN) beta-1a product (Rebif New Formulation; RNF) was compared with that of two approved recombinant human IFN beta-1a products (Rebif and Avonex). Immunogenic potential was assessed based on time to development of neutralizing antibodies (NAbs) and NAb titer. Female BALB/c mice (six in each group) received RNF, Rebif or Avonex (1.0 microg/mL subcutaneously three times weekly), and serum samples collected on Days 7, 21, and 35 (Study 1), or 28, 42, 49, and 60 (Study 2) were assayed for NAbs. In Study 1, no mice had NAbs at Day 7, but by Day 21 one mouse in the RNF group had NAbs, compared with three and four mice in the Rebif and Avonex groups, respectively. Results were similar in Study 2. All control mice were NAb negative; all actively treated mice had NAbs by day 35 or 42. Throughout Study 1, NAb titers were lowest in the RNF group and highest in the Avonex group, and at day 35, NAb titers were significantly lower in the RNF group than the Rebif group (p = 0.037). Results indicate that, on a gram-for-gram basis, RNF appears less immunogenic than Rebif or Avonex.

Evaluación de la respuesta inmune celular inducida en ratones Balb/C por la proteína de envoltura del virus dengue 2 / Assessment of the cellular immune response induced in Balb/C mice with dengue virus 2 envelope protein

The cellular immune response to dengue type 2 virus envelope protein was studied. To this end, the lympho-proliferative capacity of T-lymphocytes obtained from splenocytes of animals immunized with the protein when they were stimulated by such protein and dengue 2 virus. It was realized that splenocytes proliferated significantly in response to both types of viral antigens and that the values of stimulation indexes were higher in response to the whole virus than to the protein alone. Based on the above-mentioned, it was concludes that purified dengue 2 virus envelope protein was capable of generating specific and memory responses of antigen T-cell to dengue 2 type virus.

[Assessment of the cellular immune response induced in Balb/C mice with dengue virus 2 envelope protein]. / Evaluación de la respuesta inmune celular inducida en ratones Balb/C por la proteína de envoltura del virus dengue 2.

The cellular immune response to dengue type 2 virus envelope protein was studied. To this end, the lympho-proliferative capacity of T-lymphocytes obtained from splenocytes of animals immunized with the protein when they were stimulated by such protein and dengue 2 virus. It was realized that splenocytes proliferated significantly in response to both types of viral antigens and that the values of stimulation indexes were higher in response to the whole virus than to the protein alone. Based on the above-mentioned, it was concludes that purified dengue 2 virus envelope protein was capable of generating specific and memory responses of antigen T-cell to dengue 2 type virus.

Detection of circulating schistosome antigens in serum and urine of schistosomiasis patients and assessment of cure by a monoclonal antibody.

From a panel of monoclonal antibodies (MAb), an IgM monoclonal antibody (7F1/6B) reactive with repetitive epitopes on S. mansoni soluble egg antigen was selected. This MAb was employed both as antigen capture and detection antibody in a sandwich ELISA and had a detection limit < 1 ng S. mansoni SEA/mi. Serum and urine samples were collected from rural students who had S. mansoni (169 subjects) or mixed S. mansoni and S. haematobium (64 subjects) infections. Samples were collected before and at 4, 8 and 12 weeks after praziquantel therapy. Circulating schistosome antigens (CSA) were demonstrated in 90% of sera and 97% of urine samples of S. mansoni group and in 91% of sera and 100% of urine samples of mixed infection group. All sera from 29 uninfected individuals, 30 patients with other parasites and 70% of 55 S. haematobium-infected subjects were negative in this assay. CSA level in serum and urine samples correlated positively with the number of S. mansoni eggs/g stool in both groups. A significant reduction in CSA level was observed in serum and urine samples after praziquantel therapy. By 12 weeks post-treatment, negativity was 98% in sera and 97% in urine of S. mansoni-infected group and 98% in sera and 91% in urine of mixed infection group. The data demonstrate that the use of MAb 7F1/6B for the detection of CSA provides a sensitive method for immunodiagnosis of schistosomiasis and monitoring of cure.